Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second cancers following antineoplastic therapy.

F A Dorr, C A Coltman

    Current Problems in Cancer
    |February 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
    Same author

    Forced degradation study and characterization of main impurities of ibuprofen soft gelatin capsules by LC-MS-QTOF.

    Die Pharmazie·2021
    Same author

    A metal-free blue chromophore derived from plant pigments.

    Science advances·2020
    Same author

    Potential antiproliferative activity of polyphenol metabolites against human breast cancer cells and their urine excretion pattern in healthy subjects following acute intake of a polyphenol-rich juice of grumixama (Eugenia brasiliensis Lam.).

    Food & function·2017
    Same author

    Perspectives of digestive pest control with proteinase inhibitors that mainly affect the trypsin-like activity of Anticarsia gemmatalis Hübner (Lepidoptera: Noctuidae).

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2005
    Same author

    Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

    Alimentary pharmacology & therapeutics·2002
    Same journal

    When should the medical oncologist call the surgeon?

    Current problems in cancer·2026
    Same journal

    Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

    Current problems in cancer·2026
    Same journal

    Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

    Current problems in cancer·2026
    Same journal

    Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

    Current problems in cancer·2026
    Same journal

    Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

    Current problems in cancer·2026
    Same journal

    Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

    Current problems in cancer·2026
    See all related articles

    Intensive cancer treatments like chemotherapy and radiotherapy can increase the risk of developing secondary cancers. Balancing treatment benefits against the risk of these treatment-related malignancies is crucial for patient survival.

    Area of Science:

    • Oncology
    • Carcinogenesis
    • Cancer Treatment

    Background:

    • Metachronous malignancies, or cancers developing after an initial diagnosis, are of significant clinical interest.
    • Prolonged patient survival due to intensive therapies highlights the long-term toxicities, including secondary cancers.
    • Understanding treatment-related carcinogenesis is vital for optimizing patient outcomes.

    Purpose of the Study:

    • To review the phenomenon of metachronous malignancies and their link to cancer therapies.
    • To discuss the carcinogenic potential of specific chemotherapy agents and radiotherapy.
    • To evaluate the risk-benefit balance of intensive cancer treatments concerning secondary malignancies.

    Main Methods:

    • Literature review and synthesis of existing data on treatment-related cancers.

    Related Experiment Videos

  • Analysis of the role of alkylating agents and procarbazine in carcinogenesis.
  • Examination of the dose-response relationship for radiation and chemotherapy in cancer induction.

    • Main Results:

    • Alkylating agents and procarbazine are implicated in causing secondary cancers in humans.
    • Treatment intensity, including duration and total dose, significantly influences carcinogenesis.
    • Combined intensive chemotherapy and radiotherapy present the highest risk for secondary hematologic and solid tumors.

    Conclusions:

    • The benefits of potentially carcinogenic cancer therapies currently outweigh the risks.
    • Further research into less carcinogenic treatment combinations, like ABVD for Hodgkin's disease, is warranted.
    • Future adjuvant therapy trials should consider dose-response relationships to minimize secondary cancer risks.